Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: mRNA vaccines - CureVac

Drug Profile

Research programme: mRNA vaccines - CureVac

Alternative Names: CV-7302; RNActive® cancer immunotherapy; RNActive® infectious disease vaccines; RNActive® prophylactic vaccines

Latest Information Update: 05 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CureVac
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Influenza A vaccines; RNA vaccines; Rotavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza A virus infections
  • Research Malaria; Rotavirus infections
  • No development reported Cancer; HIV infections
  • Discontinued Respiratory syncytial virus infections

Most Recent Events

  • 05 Mar 2024 Early research is ongoing for Malaria, Influenza A virus infections and Rotavirus infections in Germany (CureVac pipeline, March 2024)
  • 28 Jul 2023 No recent reports of development identified for preclinical development in Cancer in Germany
  • 19 Jul 2023 Discontinued - Preclinical for Respiratory syncytial virus infections (Prevention) in Germany (unspecified route) (CureVac pipeline, July 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top